ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) and Bausch Health Cos (NYSE:BHC – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, risk, valuation, profitability and institutional ownership.
Volatility and Risk
ARS Pharmaceuticals has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500. Comparatively, Bausch Health Cos has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500.
Insider & Institutional Ownership
68.2% of ARS Pharmaceuticals shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are held by institutional investors. 33.8% of ARS Pharmaceuticals shares are held by insiders. Comparatively, 20.7% of Bausch Health Cos shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| ARS Pharmaceuticals | -184.24% | -256.67% | -69.63% |
| Bausch Health Cos | -10.12% | -561.95% | 6.31% |
Earnings & Valuation
This table compares ARS Pharmaceuticals and Bausch Health Cos”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ARS Pharmaceuticals | $84.28 million | 4.63 | -$171.30 million | ($2.18) | -1.80 |
| Bausch Health Cos | $10.27 billion | 0.21 | $157.00 million | ($2.96) | -1.99 |
Bausch Health Cos has higher revenue and earnings than ARS Pharmaceuticals. Bausch Health Cos is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings and recommmendations for ARS Pharmaceuticals and Bausch Health Cos, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ARS Pharmaceuticals | 1 | 1 | 4 | 0 | 2.50 |
| Bausch Health Cos | 1 | 5 | 0 | 1 | 2.14 |
ARS Pharmaceuticals presently has a consensus price target of $25.00, indicating a potential upside of 536.94%. Bausch Health Cos has a consensus price target of $8.00, indicating a potential upside of 35.71%. Given ARS Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts plainly believe ARS Pharmaceuticals is more favorable than Bausch Health Cos.
Summary
ARS Pharmaceuticals beats Bausch Health Cos on 9 of the 15 factors compared between the two stocks.
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
About Bausch Health Cos
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Receive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
